Highness Microelectronics IPO, which opened recently, has generated moderate interest among investors. The issue is part of the SME segment and targets niche participation.
Highness Microelectronics IPO, which opened recently, has generated moderate interest among investors. The issue is part of the SME segment and targets niche participation.
Manipal Health Enterprises has filed for a large IPO worth over $1 billion, making it one of the biggest healthcare listings in India. The move highlights strong growth in the healthcare sector.
Sai Parenterals IPO is set to close today, but the issue has received a relatively muted response from investors. Subscription levels remained weak during the initial days.
Wipro shares saw a marginal increase in recent trading sessions but underperformed compared to the broader market rally. The stock has been moving cautiously amid sectoral competition.
Bajaj Finserv shares remained in focus today as part of key stocks being tracked by investors amid market volatility. Movement in financial stocks continues to influence overall market direction.
Cipla remains in focus after analysts revised their target price downward, citing short-term supply challenges affecting key products. The revision reflects cautious near-term expectations.
Volatility in Indian markets has increased significantly, with investors shifting towards safer assets amid uncertainty. The ongoing geopolitical situation has led to nervousness across global markets.
Indian stock markets opened sharply lower today, with the Sensex falling over 800 points and the Nifty slipping below the 23,100 level. The decline was driven by rising geopolitical tensions between the US and Iran, which impacted global sentiment.
Crude oil prices have surged again due to supply concerns linked to Middle East tensions. This rise is adding pressure on global and Indian equity markets.
UBS on Pharma
Generic GLP-1 likely a highly competitive market; assume sector coverage
Sun Pharma – (Buy) – Looks well-positioned, with innovative medicines and a robust pipeline to support earnings
Cipla – (Neutral) – To face near-term lanreotide supply disruptions, but product launches from late FY27E are healthy
For those of you who are serious about having more, doing more, giving more and being more, success is achievable with some understanding of what to do.
